Guinea-Bissau vs SEAR: Hepatitis B surface antigen (HBsAg) prevalence
Guinea-Bissau
2.7%
in 2024
SEAR
0.2%
in 2024
Guinea-Bissau rank
8th
SEAR rank
8th
Hepatitis B surface antigen (HBsAg) prevalence over time
- Guinea-Bissau
- SEAR
How they compare
Guinea-Bissau currently reports 2.7% against 0.2% in SEAR, a difference of 2.5%.
That makes Guinea-Bissau's figure about 13.5 times SEAR's.
Across all 10 years both countries report, Guinea-Bissau has been ahead every year.
Guinea-Bissau ranks 8th and SEAR ranks 8th of 194 countries.
Guinea-Bissau has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | SEAR | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2.8% | 0.4% | 2.4% | Guinea-Bissau |
| 2020s | 2.7% | 0.3% | 2.5% | Guinea-Bissau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Guinea-Bissau or SEAR?
- Guinea-Bissau, at 2.7% against 0.2% in SEAR as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Guinea-Bissau and SEAR?
- 2.5%, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and SEAR?
- 10 years are reported by both, from 2015 to 2024.
- How do Guinea-Bissau and SEAR rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Guinea-Bissau ranks 8th and SEAR ranks 8th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.